James M Lenhard

Title: Innovator Spotlight: James M. Lenhard

Introduction: James M. Lenhard is a notable inventor based in Fort Washington, PA, who has made a contribution to the field of medical sciences through his innovative patent. His work focuses specifically on methods using alpha-methylglucoside (AMG) as a critical indicator for glucose absorption and excretion, which holds significant implications for diagnosing related diseases.

Latest Patents: Lenhard holds a patent for "Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion." This patent details methods of employing AMG in vivo to identify glucose absorption from the gastrointestinal system and its subsequent excretion via urine after oral administration. The applications of these methods extend to evaluating the effectiveness of sodium-dependent glucose transporter (SGLT) inhibitors and diagnosing diseases linked with glucose absorption and excretion.

Career Highlights: Currently, James M. Lenhard is associated with Janssen Pharmaceutica NV, a global leader in pharmaceuticals known for its commitment to innovation in health care. His work within the organization has been pivotal in advancing medical understanding and improving patient outcomes through innovative approaches.

Collaborations: In his career, Lenhard has collaborated with esteemed coworkers, including Keith T. Demarest and Gregory C. Leo. These partnerships reflect a collective effort toward pioneering advancements in medical research and enhancement of therapeutic techniques.

Conclusion: James M. Lenhard’s groundbreaking contributions, particularly through his patent related to alpha-methylglucoside, underscore the importance of innovation in healthcare. His work at Janssen Pharmaceutica NV, along with valued collaborations, continues to drive forward the frontier of medical science, making significant strides in the understanding and treatment of glucose-related conditions.